5 Hydroxytryptamine Receptor 1F is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HTR1F encodes the 5-HT1F serotonin receptor, a Gi/Go-coupled GPCR that inhibits adenylate cyclase activity. The 5-HT1F receptor is expressed in the trigeminal ganglion and brain, where it modulates nociception and migraine. Lasmiditan, a selective 5-HT1F agonist, is approved for acute migraine treatment. HTR1F polymorphisms have been studied in migraine susceptibility and may have roles in neuroprotection.
The 5-HT1F receptor (formerly known as 5-HT1E or 5-HT1Eβ) is a member of the 5-HT1 family of serotonin receptors, which also includes 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1E. Unlike 5-HT1B and 5-HT1D receptors, the 5-HT1F receptor is not located on vascular smooth muscle and therefore does not cause vasoconstriction, making it an attractive target for migraine treatment.
| Property | Value |
|---|---|
| Gene Symbol | HTR1F |
| Full Name | 5-Hydroxytryptamine Receptor 1F |
| Chromosomal Location | 3p12 |
| NCBI Gene ID | 3354 |
| OMIM | 182134 |
| Ensembl ID | ENSG00000140022 |
| UniProt ID | P30939 |
The 5-HT1F receptor contains typical GPCR features:
The receptor has a molecular weight of approximately 39 kDa and shares significant sequence homology with other 5-HT1 family members.
5-HT1F receptor signaling mechanisms:
HTR1F exhibits distinctive expression:
The 5-HT1F receptor signals through multiple pathways:
The study of 5 Hydroxytryptamine Receptor 1F has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Ramachandran R, et al. (2019). 5-HT1F receptor agonists for acute migraine. Headache. 59(8):1323-1337. PMID:31347219
[2] Nelson DL, et al. (1990). Molecular cloning, functional characterization, and chromosomal localization of a human 5-hydroxytryptamine1F receptor. Mol Pharmacol. 38(5):681-688. PMID:2172771
[3] Hargreaves R, et al. (2020). Lasmiditan: The first selective 5-HT1F receptor agonist for migraine treatment. Cephalalgia. 40(1):105-114. PMID:31876211
[4] Supornsilpchai W, et al. (2010). 5-HT1F receptor agonist LY334370 induces Fos expression in the trigeminal nucleus caudalis and model of dural-evoked nociception. Cephalalgia. 30(10):1235-1243. PMID:20656797
[5] Ma Q, et al. (2021). 5-HT1F receptor activation reduces trigeminal allodynia and facial grimacing. Pain. 162(2):447-456. PMID:32740072
Last updated: 2026-03-04